1) Wockhardt said it had agreed with the UK government to fill-finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. "As per the terms of the agreement, the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech, and licensed by AstraZeneca," the company said.2) Tata Motors reported better than expected Q1 results. Tata JLR EBITDA and EBITDA margin ahead of expectation. Company reported consol revenues declined ~48% YoY to Rs32000cr (expectation Rs25400cr), Consol EBITDA declined 79% YoY to Rs640cr – expectation loss Rs3010cr, Consol Adj. Net loss at Rs8380cr vs estimates Rs9800cr. JLR net realizations grew 20% YoY (+28% QoQ) to GBP58.5k (v/s est GBP49.2k). JLR net revenues declined 44% YoY to GBP2.9b (v/s est GBP2.4b). JLR EBITDA margins at 3.5% (-70bp YoY, -130bp QoQ, v/s est -3.6%). Beat on EBITDA was driven by a strong mix and cost cutting of GBP500m. S/A business revenues declined 80% YoY to Rs2670cr (v/s estimates Rs2240cr), EBITDA loss at Rs700cr vs estimates loss Rs1170cr & Net loss of Rs2140cr vs Rs2550cr. &Wockhardt #MOMarketUpdates #Indiastockmarket #Tatamotors #Nifty50 #NSE #BSE #Nifty #Sensex
Posted On: 03 Aug 2020 5:22 PM